Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Rezolve AI reported on October 6 and the stock has bounced 8% to $2.23, yet the short interest register has barely flinched, which is the most telling fact about where this name stands right now.
The post-earnings relief is real but modest. RZLV gained 5% on the week and is up 1% on the month, a sharp reversal from the 27%-lower setup that framed the pre-earnings notes filed earlier this week. What has not reversed is the short position. Short interest rose another 1.8% on Monday alone and is now 35% larger than it was a month ago, sitting at 14% of free float. Bears absorbed the September borrow spike (cost to borrow hit 71.8% on September 9), held through the normalisation, held through the print, and have not retreated. The ORTEX short score of 78.4 places the stock in the second percentile of the universe, meaning roughly 98% of names carry less bearish positioning. That is structural, not episodic.
The borrow market has loosened relative to the pre-earnings trough but remains genuinely tight. Availability is running at 25%, meaning only one share is available to lend for every four already out. A week ago availability had dropped to 16% as shorts jostled for borrows ahead of the print. The partial loosening since then reflects some short covering at the margin, not a change in the underlying conviction: cost to borrow has eased 13% on the week to 18.2%, but that is still 33% above where it was a month ago. The 52-week low on availability was 0.07%, hit during the most intense phase of the September borrow squeeze, and the current reading is a long way from loose. Options traders are not adding to the directional story in either direction. The put/call ratio of 0.25 is exactly in line with its 20-day average, a z-score of 0.4, which says options positioning is neutral and has been for weeks.
The ownership picture carries its own complications. Daniel Wagner, CEO, filed a Schedule 13D/A on August 28 showing his stake had slipped from 15.6% to 13.8% of the class, the fourth filing since March 2025. That is an activist 13D filer trimming his position, which is newsworthy: a Schedule 13D signals intent to influence the company, so any reduction in the position is worth tracking. Alejandro Gonzalez added 7.25 million shares in the quarter to July 14, lifting his reported stake to 7.5%. Alyeska Investment Group cut its stake from 7.57% to 4.44% as of February, falling below the 5% threshold. Citadel similarly trimmed from 5.5% to 0.5%. The register as disclosed shows concentrated insider ownership at the top, a CEO who is a 13D filer but shrinking his position, and institutional momentum traders exiting. As always with 13D/G filings, stakes are as last disclosed and holders below 5% may not file again.
The stock's only earnings reaction on record produced a 19% one-day fall and a 20% five-day fall, the print that preceded the current bearish positioning cycle. With the October 6 results now in and the stock up 8%, the market's initial read is clearly more constructive than that prior episode. But shorts have not covered and the cost of carrying a short remains high at 18%, which means conviction on both sides is being tested. The next scheduled print is December 2.
What to watch next is whether the short interest figure, which has risen 35% in a month despite an expensive borrow, begins to unwind materially in the days following the print, or whether bears use the post-earnings bounce to add further at a slightly higher price.
See the live data behind this article on ORTEX.
Open RZLV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
